MLAB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

63.00M

+0.25%

0.277

-189.25%

64.45M

+3.73%

0.353

-126.97%

62.65M

+5.22%

0.325

-61.76%

Estimates Revision

The market is revising Downward the revenue expectations for Mesa Laboratories, Inc. (MLAB) for FY2026, with the revenue forecasts being adjusted by -0.51% over the past three months. During the same period, the stock price has changed by 13.30%.

Revenue Estimates for FY2026

Revise Downward

-0.51%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+9.89%

In Past 3 Month

Stock Price

Go Up

+13.30%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

115.00

Averages

115.00

High

115.00

Current: 0.000

Low

115.00

Averages

115.00

High

115.00

Wells Fargo

Equal Weight

maintain

$75 -> $83

2025-12-15

Reason

Wells Fargo

Price Target

$75 -> $83

2025-12-15

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Mesa Labs to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Jefferies

Tycho Peterson

Buy

maintain

$110 -> $115

2025-11-07

Reason

Jefferies

Tycho Peterson

Price Target

$110 -> $115

2025-11-07

maintain

Buy

Reason

Jefferies analyst Tycho Peterson raised the firm's price target on Mesa Labs to $115 from $110 and keeps a Buy rating on the shares following a Q2 report that were "solid" and "a relatively less noisy showing than 1Q results." The firm sees scope for shares to re-rate higher as stability comes back and credibility builds, the analyst tells investors.

Wells Fargo

Underweight -> Equal Weight

upgrade

$100 -> $67

2025-08-07

Reason

Wells Fargo

Price Target

$100 -> $67

2025-08-07

upgrade

Underweight -> Equal Weight

Reason

Wells Fargo upgraded Mesa Labs to Equal Weight from Underweight with a price target of $67, down from $100. The firm believes the recent sharp stock selloff appears overdone in the context of relatively stable fundamentals and clear balance sheet flexibility for Mesa Labs to redeem its outstanding converts due next week. Wells sees a more balanced risk/reward here at about 8-times EBITDA.

Wells Fargo

Brandon Couillard

Underweight

downgrade

$120 -> $100

2025-05-30

Reason

Wells Fargo

Brandon Couillard

Price Target

$120 -> $100

2025-05-30

downgrade

Underweight

Reason

Wells Fargo analyst Brandon Couillard lowered the firm's price target on Mesa Labs to $100 from $120 and keeps an Underweight rating on the shares. The firm notes Q4 revenues were in line, but adjusted EBITDA missed by about $2M, driven by higher-than-expected bonus accrual. Shares traded sharply lower, which Wells attributes to weak Q4 margins.

Valuation Metrics

The current forward P/E ratio for Mesa Laboratories Inc (MLAB.O) is 62.30, compared to its 5-year average forward P/E of 32.35. For a more detailed relative valuation and DCF analysis to assess Mesa Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

32.35

Current PE

62.30

Overvalued PE

49.32

Undervalued PE

15.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

19.19

Current EV/EBITDA

9.51

Overvalued EV/EBITDA

26.11

Undervalued EV/EBITDA

12.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.23

Current PS

1.73

Overvalued PS

6.60

Undervalued PS

1.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MLAB News & Events

Events Timeline

No data

News

8.0

01-07Globenewswire

Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share

1.0

2025-12-19Globenewswire

Mesa Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026

1.0

2025-12-19Newsfilter

Mesa Laboratories to Present at 44th Annual J.P. Morgan Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Mesa Laboratories Inc (MLAB) stock price today?

The current price of MLAB is 81.19 USD — it has decreased -3.67 % in the last trading day.

What is Mesa Laboratories Inc (MLAB)'s business?

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

What is the price predicton of MLAB Stock?

What is Mesa Laboratories Inc (MLAB)'s revenue for the last quarter?

Mesa Laboratories Inc revenue for the last quarter amounts to 60.74M USD, increased 5.02 % YoY.

What is Mesa Laboratories Inc (MLAB)'s earnings per share (EPS) for the last quarter?

Mesa Laboratories Inc. EPS for the last quarter amounts to 0.45 USD, decreased -28.57 % YoY.

What changes have occurred in the market's expectations for Mesa Laboratories Inc (MLAB)'s fundamentals?

How many employees does Mesa Laboratories Inc (MLAB). have?

Mesa Laboratories Inc (MLAB) has 730 emplpoyees as of January 10 2026.

What is Mesa Laboratories Inc (MLAB) market cap?

Today MLAB has the market capitalization of 448.36M USD.